Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 1 (January)

1. Isoform specific changes in PPAR alpha and beta in colon and breast cancer with differentiation.
   Biochem Biophys Res Commun, 340(2): 656-60. [Abstract] [Full-text]
2. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort.
   J Natl Cancer Inst, 98(1): 69-72. [Abstract] [Full-text]
3. Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
   J Med Chem, 49(1): 179-85. [Abstract] [Full-text]
4. Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease.
   Am J Clin Pathol, 125(2): 229-33. [Abstract] [Full-text]
5. Erybraedin C and bitucarpin A, two structurally related pterocarpans purified from Bituminaria bituminosa, induced apoptosis in human colon adenocarcinoma cell lines MMR- and p53-proficient and -deficient in a dose-, time-, and structure-dependent fashion.
   Chem Biol Interact, 159(2): 104-16. [Abstract] [Full-text]
6. Altered gene expression in normal colonic mucosa of individuals with polyps of the colon.
   Dis Colon Rectum, 48(12): 2329-35. [Abstract] [Full-text]
7. The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision.
   Dis Colon Rectum, 48(12): 2249-57. [Abstract] [Full-text]
8. Pinealoblastoma in a patient with familial adenomatous polyposis: variant of Turcot syndrome type 2? Report of a case and review of the literature.
   Dis Colon Rectum, 48(12): 2343-6. [Abstract] [Full-text]
9. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer.
   Dis Colon Rectum, 48(12): 2197-208. [Abstract] [Full-text]
10. Immunogenic hsp-70 is overexpressed in colorectal cancers with high-degree microsatellite instability.
    Dis Colon Rectum, 48(12): 2322-8. [Abstract] [Full-text]
11. Quality of life of patients operated on for low rectal cancer: impact of the type of surgery and patients' characteristics.
    Dis Colon Rectum, 48(12): 2180-91. [Abstract] [Full-text]
12. Colorectal polyps in carriers of the APC I1307K polymorphism.
    Dis Colon Rectum, 48(12): 2317-21. [Abstract] [Full-text]
13. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients.
    Dis Colon Rectum, 48(12): 2238-48. [Abstract] [Full-text]
14. Laparoscopic vs. open colectomy in cancer patients: long-term complications, quality of life, and survival.
    Dis Colon Rectum, 48(12): 2217-23. [Abstract] [Full-text]
15. Long-term outcome after ampullectomy for ampullary lesions associated with familial adenomatous polyposis.
    Dis Colon Rectum, 48(12): 2192-6. [Abstract] [Full-text]
16. Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases.
    Dis Colon Rectum, 48(12): 2289-93. [Abstract] [Full-text]
17. Limited survival in the treatment of carcinomatosis from rectal cancer.
    Dis Colon Rectum, 48(12): 2258-63. [Abstract] [Full-text]
18. Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer.
    Dis Colon Rectum, 48(12): 2224-31. [Abstract] [Full-text]
19. Do geographic and educational factors influence the quality of life in rectal cancer patients with a permanent colostomy?
    Dis Colon Rectum, 48(12): 2209-16. [Abstract] [Full-text]
20. Optimal ligation level of the primary feeding artery and bowel resection margin in colon cancer surgery: the influence of the site of the primary feeding artery.
    Dis Colon Rectum, 48(12): 2232-7. [Abstract] [Full-text]
21. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
    J Clin Oncol, 24(2): 217-27. [Abstract] [Full-text]
22. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
    Br J Cancer, 94(1): 128-35. [Abstract] [Full-text]
23. The effect of surgically induced ischaemia on gene expression in a colorectal cancer xenograft model.
    Br J Cancer, 94(1): 121-7. [Abstract] [Full-text]
24. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
    Br J Cancer, 94(1): 69-73. [Abstract] [Full-text]
25. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials.
    Cancer Immunol Immunother, 55(4): 404-11. [Abstract] [Full-text]
26. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Cancer Chemother Pharmacol, 57(4): 491-9. [Abstract] [Full-text]
27. Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles.
    Cancer Chemother Pharmacol, 57(4): 500-6. [Abstract] [Full-text]
28. Influence of obesity on the risk of developing colon cancer.
    Gut, 55(2): 285-91. [Abstract] [Full-text]
29. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.
    Gut, 55(2): 234-42. [Abstract] [Full-text]
30. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
    Oncogene, 25(2): 165-75. [Abstract] [Full-text]
31. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1.
    Oncogene, 25(2): 278-87. [Abstract] [Full-text]
32. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Oncogene, 25(2): 304-9. [Abstract] [Full-text]
33. IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer.
    J Natl Cancer Inst, 98(2): 139-43. [Abstract] [Full-text]
34. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study.
    J Natl Cancer Inst, 98(2): 135-8. [Abstract] [Full-text]
35. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
    N Engl J Med, 354(3): 261-9. [Abstract] [Full-text]
36. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    J Clin Oncol, 24(3): 394-400. [Abstract] [Full-text]
37. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial.
    J Clin Oncol, 24(3): 386-93. [Abstract] [Full-text]
38. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon.
    Cancer Res, 66(2): 1191-8. [Abstract] [Full-text]
39. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells.
    Cancer Res, 66(2): 1033-9. [Abstract] [Full-text]
40. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice.
    Cancer Res, 66(2): 828-38. [Abstract] [Full-text]
41. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer.
    Cancer Res, 66(2): 763-9. [Abstract] [Full-text]
42. De novo CpG island methylation in human cancer cells.
    Cancer Res, 66(2): 682-92. [Abstract] [Full-text]
43. Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers.
    Cancer Res, 66(2): 659-64. [Abstract] [Full-text]
44. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.
    Cancer Res, 66(2): 632-7. [Abstract] [Full-text]
45. Magnesium intake and reduced risk of colon cancer in a prospective study of women.
    Am J Epidemiol, 163(3): 232-5. [Abstract] [Full-text]
46. Qualitative assessment of patient experiences related to extended pelvic resection for rectal cancer.
    J Surg Oncol, 93(2): 92-9. [Abstract] [Full-text]
47. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma.
    J Surg Oncol, 93(2): 151-60. [Abstract] [Full-text]
48. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
    J Surg Oncol, 93(2): 145-50. [Abstract] [Full-text]
49. Detection of venous invasion in surgical specimens of colorectal carcinoma: the efficacy of various types of tissue blocks.
    J Clin Pathol, 59(2): 207-10. [Abstract] [Full-text]
50. Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations.
    Int J Cancer, 118(7): 1653-9. [Abstract] [Full-text]
51. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Int J Cancer, 118(7): 1721-7. [Abstract] [Full-text]
52. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis.
    Int J Cancer, 118(7): 1790-7. [Abstract] [Full-text]
53. Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial.
    Int J Cancer, 118(7): 1777-81. [Abstract] [Full-text]
54. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    J Clin Oncol, 24(4): 668-74. [Abstract] [Full-text]
55. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
    J Clin Oncol, 24(4): 656-62. [Abstract] [Full-text]
56. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
    J Clin Oncol, 24(4): 650-5. [Abstract] [Full-text]
57. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States?
    J Clin Oncol, 24(4): 626-34. [Abstract] [Full-text]

© 2004-2010 Colorectal Cancer Research Today. All Rights Reserved.